Slide 1 ANCO Best of ASCO 2011 GI Oncology Abstracts Katie Kelley, M.D. Assistant Clinical Professor University of California, San Francisco 27 August 2011 Slide 2 GI Oncology…

Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…

ASCO Annual Meeting 2012 PHASE II STUDY OF PANITUMUMAB (P) IN COMBINATION WITH FOLFOXIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): HIGH ACTIVITY IN…

Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…

Anti-EGFR Antibodies in Metastatic Colorectal Cancer: Which Patients, When, and How? J. Randolph Hecht, MD David Geffen School of Medicine at UCLA Disclosures Research Funding…